In the current study, Doxil® reduced the number of Tregs, TAMs and MDSCs from tumor tissue of immunocompetent mice (Figure 2) and Doxil® skewed polarization from M2 to M1 phenotype (Supplementary Figure S2), which would lead to an increase in CD4+/CD8+ T cell-mediated antitumor immunity. The gene discussed is CD8A; the disease is neoplasm.